Thursday, May 10, 2012
ImmunoCellular Therapeutics Ltd., of Woodland Hills, Calif., said that its double-blind, placebo-controlled Phase II trial of ICT-107, a vaccine for glioblastoma multiforme, has been initiated at 25 sites, and has enrolled 189 patients. About 200 subjects will be enrolled to treat 102 patients with HLA-A1/A2 immunological subtypes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.